Novotech Appoints Commercial and Clinical Life Sciences Specialist to Head Up Global Drug Development Consulting Team
May 02 2024 - 5:00PM
Novotech Appoints Commercial and Clinical Life Sciences Specialist
to Head Up Global Drug Development Consulting Team
Novotech, the global full-service clinical Contract Research
Organization (CRO) that partners with biotech companies to
accelerate the development of advanced and novel therapeutics at
every phase, has appointed Scott Schliebner as Vice President and
Global Head, Drug Development Consulting (DDC).
Novotech’s Chief Medical Officer Dr. Judith Ng-Cashin stated:
“We welcome Scott to the medical and scientific team. He is a
proven strategic, innovative, and business focused life sciences
executive with ~30 year of experience across the biopharma and CRO
sectors. He brings valuable leadership to our world-class DDC team,
a full-service global drug development and strategic regulatory
team providing comprehensive "inception to approval" services.”
The DDC partners with biotechs to optimize a fit-for purpose
therapeutic development strategy that both advances the development
program and creates value for the company. To do this, DDC
leverages CMC/manufacturing, toxicology, clinical/medical and
regulatory affairs experts with extensive industry experience
covering all phases of drug development. It also offers a fully
integrated regulatory affairs team with an experienced, speed
orientated mindset to increase the probability of regulatory and
commercial success.
The DDC team has experience in a comprehensive range of
indications for drugs, novel antibodies, recombinant protein
therapeutics, small molecules, vaccines, cell therapy, devices, and
combination products, throughout all phases of program development
(Phases I - IV) and commercialization.
Scott Schliebner said he was extremely pleased to join the DDC
team. “I bring a strategic and consultative approach to building
and growing life sciences businesses, with a focus on developing
relationships, partnerships, and collaborations that drive
commercial success. I am also passionate about leveraging data and
technology including RWE/RWD, technological innovation, and
patient-focused paradigms to accelerate clinical drug development,”
he said.
Schliebner, who is US-based, holds a Master’s Degree in Public
Health in Biostatistics from the University of Utah School of
Medicine and completed a Graduate Research Fellowship at The
National Institutes of Health/NINDS.
https://www.linkedin.com/in/scott-schliebner-1087789/
About Novotech
Novotech-CRO.com
Founded in 1997, Novotech is a global full-service clinical
Contract Research Organization (CRO) focused on partnering with
biotech companies to accelerate the development of advanced and
novel therapeutics at every phase.
Recognized for its industry-leading contributions, Novotech has
received numerous prestigious awards, including the CRO Leadership
Award 2023, the Asia Pacific Cell & Gene Therapy Clinical
Trials Excellence 2023, the Asia-Pacific Contract Research
Organization Company of the Year Award since 2006.
The Company offers a comprehensive suite of services including
laboratories, Phase I facilities, drug development consulting,
regulatory expertise, and has experience with over 5,000 clinical
projects, including Phase I to Phase IV clinical trials and
bioequivalence studies. With a presence in 34 office locations and
a dedicated team of 3,000+ professionals worldwide, Novotech is a
trusted end-to-end strategic partner of choice.
For more information or to speak to an expert team member
visit www.Novotech-CRO.com